Home> Products> prophylactic measure

{ "products": [ { "_id": "6662e74687f0960e14a2d95a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Gefitinib 250mg", "description": "\n\nGEFISTERIS 250 is a premium pharmaceutical formulation containing Gefitinib 250mg, a breakthrough targeted therapy medication manufactured by Steris Healthcare. This innovative oral medication represents a significant advancement in the treatment of non-small cell lung cancer (NSCLC), offering patients a precise, scientifically-designed approach to combating one of the world's most challenging malignancies. GEFISTERIS 250 is specifically engineered to target the underlying molecular mechanisms that drive certain types of lung cancer, providing hope and extended survival for patients who carry specific genetic mutations.\nAs a tyrosine kinase inhibitor, GEFISTERIS 250 works at the cellular level to interrupt the signals that tell cancer cells to grow and divide. This targeted approach differs fundamentally from traditional chemotherapy, which affects both healthy and cancerous cells. By focusing specifically on cancer cells with epidermal growth factor receptor (EGFR) mutations, GEFISTERIS 250 offers a more refined treatment strategy with potentially fewer systemic side effects and improved quality of life during treatment.\nUnderstanding Gefitinib 250mg: The Science Behind GEFISTERIS 250\nGefitinib 250mg, the active pharmaceutical ingredient in GEFISTERIS 250, belongs to a revolutionary class of medications known as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). The development of this medication marked a paradigm shift in oncology, moving from one-size-fits-all chemotherapy approaches to personalized, mutation-specific treatments.\nThe EGFR protein is found on the surface of cells and plays a crucial role in cell growth and division. In normal cells, EGFR activation is carefully regulated. However, in certain lung cancers, mutations in the EGFR gene cause the receptor to remain constantly active, sending continuous signals for the cell to grow, divide, and survive—leading to uncontrolled cancer growth. GEFISTERIS 250 works by blocking the tyrosine kinase activity of the mutated EGFR protein, effectively turning off the growth signal and causing cancer cells to stop proliferating and eventually die.\nThis precision targeting is what makes GEFISTERIS 250 particularly effective for patients whose tumors harbor activating EGFR mutations, particularly the common exon 19 deletions or exon 21 L858R substitution mutations. Before initiating treatment with GEFISTERIS 250, patients undergo molecular testing to confirm the presence of these mutations, ensuring that the therapy is appropriately matched to their specific cancer biology.\nPrimary Uses and Indications of GEFISTERIS 250\nGEFISTERIS 250 is primarily indicated for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors have specific EGFR mutations. The medication is approved for both first-line treatment in newly diagnosed patients and for those whose disease has progressed after platinum-based chemotherapy.\nFirst-Line Treatment: When EGFR mutations are detected in treatment-naïve patients, GEFISTERIS 250 offers an excellent first-line option, often providing superior progression-free survival compared to traditional chemotherapy regimens. Patients starting with targeted therapy typically experience better tolerability and quality of life during initial treatment phases.\nSecond-Line and Beyond: For patients whose cancer has progressed after chemotherapy, GEFISTERIS 250 provides an effective alternative treatment option, particularly when EGFR mutation testing was not performed initially or when the mutation status was unknown at the time of first treatment.\nThe medication is taken orally as a once-daily tablet, offering significant convenience compared to intravenous chemotherapy that requires hospital visits and lengthy infusion times. This oral administration allows patients to maintain greater independence and normalcy in their daily lives while receiving effective cancer treatment.\nKey Benefits of GEFISTERIS 250\n1. Targeted Cancer Fighting Action\nThe primary benefit of GEFISTERIS 250 lies in its precision targeting mechanism. Unlike conventional chemotherapy that attacks all rapidly dividing cells in the body, GEFISTERIS 250 specifically targets cancer cells bearing EGFR mutations. This selective action means that healthy cells are largely spared, resulting in a more favorable side effect profile and better preservation of normal bodily functions during treatment.\n2. Superior Efficacy in EGFR-Mutant NSCLC\nClinical trials have consistently demonstrated that GEFISTERIS 250 and other EGFR-TKIs provide superior progression-free survival compared to chemotherapy in patients with EGFR-mutant NSCLC. Response rates typically range from 60-80% in appropriate patient populations, with many patients experiencing significant tumor shrinkage and symptomatic improvement within weeks of starting treatment.\n3. Improved Quality of Life\nPatients taking GEFISTERIS 250 often report better quality of life compared to those receiving traditional chemotherapy. The medication's targeted nature results in fewer debilitating side effects such as severe nausea, hair loss, and profound fatigue. Many patients can continue working, traveling, and engaging in normal daily activities while on treatment.\n4. Convenient Oral Administration\nGEFISTERIS 250's once-daily oral dosing eliminates the need for frequent hospital visits for intravenous chemotherapy infusions. Patients take one tablet daily at home, providing tremendous convenience and reducing the burden of treatment. This ease of administration contributes significantly to treatment adherence and patient satisfaction.\n5. Rapid Symptom Relief\nMany patients experience rapid improvement in cancer-related symptoms such as cough, shortness of breath, chest pain, and fatigue within the first few weeks of GEFISTERIS 250 treatment. This quick symptomatic relief can dramatically improve quality of life even before significant tumor shrinkage is visible on imaging studies.\n6. Extended Survival Benefits\nLong-term data demonstrates that appropriate use of EGFR-TKIs like GEFISTERIS 250 contributes to extended overall survival in patients with EGFR-mutant lung cancer. When used as part of a comprehensive treatment strategy, including potential sequential therapies after progression, patients can achieve survival times that were unimaginable before the advent of targeted therapies.\n7. Manageable Side Effect Profile\nWhile GEFISTERIS 250 does cause side effects, they are generally more manageable than those associated with traditional chemotherapy. Most side effects can be effectively controlled with supportive medications, dose modifications, or temporary treatment interruptions, allowing patients to continue benefiting from therapy.\n8. Quality Manufacturing by Steris Healthcare\nGEFISTERIS 250 benefits from Steris Healthcare's commitment to pharmaceutical excellence. Each tablet undergoes rigorous quality testing to ensure consistent potency, purity, and bioavailability. This quality assurance means patients receive reliable, effective medication with every dose.\nSide Effects of GEFISTERIS 250 (Gefitinib 250mg)\nWhile GEFISTERIS 250 offers significant therapeutic benefits, patients should be aware of potential side effects. Understanding these effects enables early recognition and appropriate management.\nCommon Side Effects (Affecting 20% or More of Patients):\nSkin Reactions: The most characteristic side effect of GEFISTERIS 250 is an acne-like rash, typically appearing on the face, chest, and back within the first few weeks of treatment. This rash, while cosmetically concerning for some patients, actually correlates with better treatment response. The rash can be managed with topical antibiotics, moisturizers, and sun protection. In severe cases, temporary dose reduction may be necessary.\nDiarrhea: Approximately 50-60% of patients experience diarrhea of varying severity. Mild diarrhea can often be managed with dietary modifications and over-the-counter anti-diarrheal medications like loperamide. Patients should stay well-hydrated and contact their healthcare provider if diarrhea becomes severe or persistent, as dose adjustments may be needed.\nNail Changes: Some patients develop paronychia (nail bed inflammation) or other nail abnormalities. Proper nail care, avoiding trauma to the nail beds, and wearing protective gloves during housework can help minimize these effects.\nDry Skin: Many patients experience skin dryness and itching. Regular use of fragrance-free moisturizers, gentle cleansers, and avoidance of hot showers can help manage these symptoms.\nMouth Sores: Oral mucositis or stomatitis can develop in some patients. Good oral hygiene, avoiding spicy or acidic foods, and using alcohol-free mouthwashes can provide relief.\nLess Common but Serious Side Effects:\nInterstitial Lung Disease (ILD): While rare (1-2% of patients), ILD is the most serious potential side effect of GEFISTERIS 250. Symptoms include sudden onset or worsening of respiratory symptoms such as difficulty breathing, cough, or fever. This requires immediate medical attention and usually necessitates permanent discontinuation of the medication.\nLiver Function Abnormalities: Elevated liver enzymes can occur, requiring regular monitoring through blood tests. Most cases are asymptomatic and reversible with dose modification or temporary discontinuation.\nEye Problems: Dry eyes, corneal erosion, or other ocular issues may develop. Regular use of lubricating eye drops and ophthalmological evaluation when symptoms occur can prevent serious complications.\nGastrointestinal Perforation: Though rare, serious gastrointestinal complications including perforation can occur, particularly in patients with underlying GI conditions.\nManagement Strategies:\nMost side effects can be effectively managed through:\n\nProactive supportive care and prophylactic measures\nDose modifications (reduction to 250mg every other day in some cases)\nTemporary treatment interruptions allowing recovery\nSymptomatic treatment with appropriate medications\nPatient education about early recognition and reporting of symptoms\n\nPatients should maintain open communication with their healthcare team, reporting any new or worsening symptoms promptly. Regular monitoring through clinical visits and laboratory testing helps identify and address side effects before they become serious.\nDosage and Administration Guidelines\nThe standard dose of GEFISTERIS 250 is one 250mg tablet taken orally once daily, with or without food. The tablet should be swallowed whole with water and should not be crushed or chewed. If a dose is missed and it's been less than 12 hours since the scheduled time, patients should take the missed dose. If more than 12 hours have passed, skip the missed dose and resume the regular schedule—never double up on doses.\nTreatment continues until disease progression or unacceptable toxicity occurs. Some patients remain on GEFISTERIS 250 for months or even years if they continue to benefit without prohibitive side effects. Dose modifications may be necessary based on individual tolerance, typically reducing the frequency to every other day rather than lowering the individual dose.\nPrecautions and Important Considerations\nPatients taking GEFISTERIS 250 should be aware of several important precautions. The medication can cause harm to developing fetuses, so women of childbearing potential must use effective contraception during treatment and for at least two weeks after the last dose. Breastfeeding should be avoided during treatment and for two weeks after completion.\nGEFISTERIS 250 can interact with medications that affect stomach acid, including proton pump inhibitors and H2-receptor antagonists. If antacids are needed, they should be taken several hours apart from GEFISTERIS 250. The medication may also interact with certain other drugs metabolized by the liver, so patients should inform their healthcare provider about all medications, supplements, and herbal products they're taking.\nRegular monitoring is essential during GEFISTERIS 250 treatment, including periodic liver function tests, pulmonary symptom assessment, and clinical evaluation for skin and other toxicities. Patients should avoid prolonged sun exposure and use high-SPF sunscreen, as the medication can increase photosensitivity.\nConclusion\nGEFISTERIS 250 represents a transformative treatment option for patients with EGFR-mutant non-small cell lung cancer, offering targeted, effective therapy with a manageable side effect profile. Manufactured by Steris Healthcare with unwavering commitment to quality and patient outcomes, GEFISTERIS 250 delivers Gefitinib 250mg in a formulation designed for optimal bioavailability and consistent therapeutic effect.\nThe medication's precision targeting of cancer-driving mutations, combined with convenient oral administration and generally tolerable side effects, makes GEFISTERIS 250 an excellent choice for eligible patients. While side effects do occur and require monitoring and management, the potential benefits—including tumor response, symptom improvement, extended progression-free survival, and enhanced quality of life—often significantly outweigh the risks for appropriately selected patients.\nSuccess with GEFISTERIS 250 requires partnership between patients and their healthcare teams. Molecular testing to confirm EGFR mutation status before treatment, adherence to the prescribed regimen, proactive management of side effects, and regular monitoring all contribute to optimal outcomes. For many patients with EGFR-mutant lung cancer, GEFISTERIS 250 offers not just treatment, but genuine hope for extended, quality life.\nAs personalized medicine continues to evolve, medications like GEFISTERIS 250 exemplify the power of matching treatments to individual tumor characteristics. Steris Healthcare's commitment to delivering this advanced therapy with assured quality and accessibility ensures that more patients can benefit from the remarkable advances in targeted cancer treatment that Gefitinib 250mg represents.\n", "price": 2760.0, "discountamount": 828.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "food", "Call", "Uses", "Rash", "Note", "NSCLC", "Email", "nausea", "Dosage", "spread", "WhatsApp", "diarrhea", "Gefitinib", "treatment", "One tablet", "GEFISTERIS", "information", "sterispharma", "consultation", "sterisonline", "Side Effects", "cancer cells", "targeted therapy", "Regular monitoring", "healthcare provider", "small cell lung cancer", "healthcare professional", "specific EGFR mutations", "epidermal growth factor receptor", "potential liver function alterations" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1530, "imageuri": "https://productimages.withfloats.com/actual/667d25ffb56721898510e93e.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d25ffb56721898510e93e.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T10:56:06.808Z", "updatedon": "2025-12-24T09:35:26.473Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gefitinib-250mg/1530", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GEFISTERIS 250", "category": "Oncology", "tags": [ "gefitinib 250 mg uses", "", "gefitinib 250 mg online purchase", "", "gefitinib 250 mg tablets price in india", "non-small cell lung cancer (NSCLC).", "triggered by chemotherapy.", "cancer biology.", "Superior Efficacy in EGFR-Mutant NSCLC" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "69942f823b20a66d9dcf9458", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Indacaterol Maleate and Glycopyrronium Bromide", "description": "GLYCOPRESS INDUS™ is a modern dual bronchodilator therapy formulated with Indacaterol Maleate and Glycopyrronium Bromide, designed for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). This advanced inhalation formulation combines two complementary mechanisms of action to deliver sustained airway relaxation, improved lung function, and enhanced breathing comfort.\n\nCOPD is a progressive respiratory condition characterized by airflow limitation, chronic inflammation, and episodes of breathlessness. Effective management requires consistent bronchodilation to keep the airways open and reduce daily symptoms. GLYCOPRESS INDUS™ addresses this need through a once-daily maintenance approach that targets airway narrowing through dual pharmacological pathways.\n\nManufactured under strict quality standards, GLYCOPRESS INDUS™ ensures reliable dosing, stability, and optimal pulmonary delivery when used with the recommended inhalation device. It is intended for regular use and not for the treatment of sudden breathing emergencies.\n\nComposition and Mechanism of Action\n\nGLYCOPRESS INDUS™ combines two long-acting bronchodilators:\n\n1. Indacaterol Maleate (Long-Acting Beta2-Agonist – LABA)\n\nIndacaterol stimulates beta2-adrenergic receptors located in the smooth muscles of the airways. Activation of these receptors causes the muscles to relax, resulting in bronchodilation. This effect:\n\nReduces airway resistance\n\nImproves airflow\n\nDecreases breathlessness\n\nSupports 24-hour bronchodilation\n\nIndacaterol is known for its rapid onset and prolonged duration of action, making it effective for once-daily therapy.\n\n2. Glycopyrronium Bromide (Long-Acting Muscarinic Antagonist – LAMA)\n\nGlycopyrronium blocks muscarinic receptors in the bronchial smooth muscles. These receptors normally respond to acetylcholine, which causes airway constriction. By inhibiting this response, glycopyrronium:\n\nPrevents bronchospasm\n\nReduces airway tightening\n\nPromotes sustained airway relaxation\n\nDual-Action Advantage\n\nThe combination of LABA and LAMA in GLYCOPRESS INDUS™ provides enhanced bronchodilation compared to either agent alone. While indacaterol actively relaxes airway muscles, glycopyrronium prevents them from tightening. This complementary action ensures comprehensive and sustained airway management.\n\nIndications and Uses\n\nGLYCOPRESS INDUS™ is indicated for:\n\nMaintenance treatment of chronic obstructive pulmonary disease (COPD)\n\nChronic bronchitis management\n\nEmphysema management\n\nLong-term airflow limitation therapy\n\nIt is important to understand that GLYCOPRESS INDUS™:\n\nIs not a rescue inhaler\n\nShould not be used for sudden acute bronchospasm\n\nIs not intended for primary asthma treatment unless prescribed by a physician\n\nPatients should always keep a short-acting bronchodilator available for emergency relief.\n\nKey Benefits of GLYCOPRESS INDUS™\n1. Once-Daily Dosing Convenience\n\nGLYCOPRESS INDUS™ is formulated for once-daily administration, improving adherence and simplifying treatment routines.\n\n2. Dual Bronchodilation for Superior Airway Control\n\nThe LABA + LAMA combination provides broader and more effective airway relaxation compared to single-agent therapy.\n\n3. Rapid Onset with Sustained Effect\n\nIndacaterol provides quick bronchodilation, while glycopyrronium maintains airway openness for up to 24 hours.\n\n4. Improved Lung Function\n\nRegular use can enhance lung performance parameters, such as improved airflow measurements and reduced air trapping.\n\n5. Reduced Breathlessness\n\nPatients may experience decreased shortness of breath during physical activities, leading to greater independence.\n\n6. Lower Frequency of COPD Exacerbations\n\nConsistent airway maintenance can help reduce the likelihood of flare-ups and hospital visits.\n\n7. Enhanced Quality of Life\n\nBetter breathing control contributes to improved sleep, increased exercise tolerance, and overall well-being.\n\nDosage and Administration\n\nGLYCOPRESS INDUS™ should be used exactly as prescribed by a healthcare professional.\n\nGeneral Administration Guidelines:\n\nUse once daily at the same time each day.\n\nInhale using the provided inhalation device.\n\nDo not swallow capsules (if capsule-based system).\n\nDo not exceed the recommended dose.\n\nFollow inhaler technique instructions carefully.\n\nProper inhalation technique is essential for effective drug delivery. Healthcare providers should demonstrate correct usage during initial prescription.\n\nPossible Side Effects\n\nWhile GLYCOPRESS INDUS™ is generally well tolerated, some individuals may experience side effects.\n\nCommon Side Effects\n\nDry mouth\n\nCough\n\nThroat irritation\n\nHeadache\n\nNasal congestion\n\nMild tremor\n\nDizziness\n\nThese symptoms are often mild and may diminish with continued use.\n\nCardiovascular Effects\n\nDue to the beta2-agonist component (indacaterol), some patients may experience:\n\nIncreased heart rate\n\nPalpitations\n\nMild fluctuations in blood pressure\n\nPatients with pre-existing heart conditions should consult their physician before starting therapy.\n\nAnticholinergic Effects (from Glycopyrronium)\n\nDifficulty urinating\n\nBlurred vision\n\nWorsening of narrow-angle glaucoma\n\nIndividuals with urinary retention or glaucoma should use caution.\n\nRare but Serious Reactions\n\nParadoxical bronchospasm (worsening breathing immediately after inhalation)\n\nSevere allergic reactions\n\nSignificant cardiac rhythm disturbances\n\nImmediate medical attention should be sought if severe reactions occur.\n\nPrecautions and Warnings\n\nBefore starting GLYCOPRESS INDUS™, inform your healthcare provider if you have:\n\nCardiovascular disease\n\nArrhythmias\n\nHypertension\n\nHyperthyroidism\n\nDiabetes\n\nSeizure disorders\n\nGlaucoma\n\nProstate enlargement\n\nKidney impairment\n\nDrug Interactions\n\nCaution is required when using:\n\nOther long-acting beta2-agonists\n\nOther anticholinergic medications\n\nBeta-blockers\n\nDiuretics\n\nCertain antidepressants (e.g., MAO inhibitors)\n\nAlways provide a complete list of medications and supplements to your healthcare provider.\n\nWho Should Use GLYCOPRESS INDUS™?\n\nGLYCOPRESS INDUS™ is ideal for:\n\nAdults with moderate to severe COPD\n\nPatients not adequately controlled on single bronchodilator therapy\n\nIndividuals seeking a once-daily maintenance inhaler\n\nPatients requiring dual bronchodilation for improved symptom control\n\nIt is not typically recommended for pediatric patients unless specifically directed by a healthcare professional.\n\nIntegrating GLYCOPRESS INDUS™ into COPD Management\n\nFor optimal results, GLYCOPRESS INDUS™ should be part of a comprehensive COPD management plan that includes:\n\nSmoking cessation\n\nPulmonary rehabilitation programs\n\nRegular physical activity\n\nBalanced nutrition\n\nScheduled medical follow-ups\n\nAdherence to therapy and routine monitoring significantly improve long-term outcomes.\n\nStorage Instructions\n\nStore at room temperature\n\nProtect from moisture and direct sunlight\n\nKeep in original packaging until use\n\nKeep out of reach of children\nConclusion\nGLYCOPRESS INDUS™ (Indacaterol Maleate + Glycopyrronium Bromide) is a powerful dual bronchodilator designed to provide sustained airway control in individuals living with chronic obstructive pulmonary disease. By combining a long-acting beta2-agonist and a long-acting muscarinic antagonist, it offers comprehensive bronchodilation through two complementary pathways.", "price": 703.0, "discountamount": 211.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2308, "imageuri": "https://productimages.withfloats.com/actual/69942f8410196f5f212c916f.png", "tileimageuri": "https://productimages.withfloats.com/tile/69942f8410196f5f212c916f.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-02-17T09:06:10.4Z", "updatedon": "2026-02-17T09:06:10.4Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/indacaterol-maleate-and-glycopyrronium-bromide/2308", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLYCOPRESS INDUS", "category": "ASTHMARANGE", "tags": [ "indacaterol maleate and glycopyrronium bromide inhalation powder dosage", "indacaterol maleate and glycopyrronium bromide dry powder inhaler use", "indacaterol maleate and glycopyrronium bromide COPD maintenance therapy", "indacaterol maleate and glycopyrronium bromide combination therapy side effects", "indacaterol maleate and glycopyrronium bromide unit dose inhalation capsules", "indacaterol maleate and glycopyrronium bromide nebulization instructions", "what is indacaterol maleate and glycopyrronium bromide used for", "how to use indacaterol maleate and glycopyrronium bromide inhaler", "buy indacaterol maleate and glycopyrronium bromide inhaler online" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6979ab153e3091701b89e481", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Misoprostol Tablet 200 mcg", "description": "MISOPIRATE 200 is a pharmaceutical preparation containing Misoprostol 200 mcg, a synthetic prostaglandin E1 analogue that has revolutionized women's healthcare and gastrointestinal treatment protocols. This medication represents a critical therapeutic option in modern medicine, offering solutions for conditions ranging from gastric ulcer prevention to obstetric and gynecological applications. Each tablet of MISOPIRATE 200 is precisely formulated to deliver consistent therapeutic benefits while maintaining strict quality standards.Misoprostol, the active ingredient in MISOPIRATE 200, was initially developed for protecting the gastric lining but has since become indispensable in reproductive healthcare. The medication works by mimicking natural prostaglandins in the body, which are hormone-like substances that regulate various physiological processes including gastric acid secretion, cervical ripening, and uterine contractions.Mechanism of ActionMISOPIRATE 200 functions through multiple pathways depending on the clinical indication. In the gastrointestinal system, it reduces gastric acid secretion by directly inhibiting parietal cells in the stomach lining. Simultaneously, it enhances the production of protective mucus and bicarbonate, creating a defensive barrier against acid-induced damage. This dual action makes it exceptionally effective in preventing and treating peptic ulcers, particularly those induced by nonsteroidal anti-inflammatory drugs (NSAIDs).In obstetric and gynecological applications, MISOPIRATE 200 acts on prostaglandin receptors in the uterus and cervix. It causes the cervix to soften and dilate while stimulating rhythmic uterine contractions. These properties make it valuable for medical management of early pregnancy complications, labor induction, and postpartum hemorrhage prevention.Clinical Uses and ApplicationsGastric Protection: MISOPIRATE 200 serves as a prophylactic agent for individuals requiring long-term NSAID therapy who are at elevated risk for developing gastric or duodenal ulcers. Patients with rheumatoid arthritis, osteoarthritis, or chronic pain conditions who depend on NSAIDs benefit significantly from concurrent misoprostol therapy.Peptic Ulcer Treatment: The medication accelerates healing of existing gastric ulcers by reducing acid exposure and promoting mucosal regeneration. Treatment typically spans four to eight weeks, depending on ulcer severity and individual response.Medical Management of Early Pregnancy Loss: Under strict medical supervision, MISOPIRATE 200 is utilized for managing incomplete miscarriage or missed abortion, offering a non-surgical alternative that many women prefer for emotional and practical reasons.Labor Induction: In hospital settings, healthcare providers may use MISOPIRATE 200 to ripen the cervix and initiate labor when medically indicated, such as in cases of post-term pregnancy or maternal health concerns.Postpartum Hemorrhage Prevention: The medication's ability to promote uterine contractions makes it valuable in preventing excessive bleeding after childbirth, particularly in resource-limited settings.Key Benefits of MISOPIRATE 200Effective Gastric Protection: MISOPIRATE 200 provides superior protection against NSAID-induced gastric damage compared to many alternatives. Clinical studies demonstrate up to 80% reduction in serious gastrointestinal complications among high-risk patients using preventive misoprostol therapy.Non-Invasive Medical Option: For women facing early pregnancy complications, MISOPIRATE 200 offers a medical alternative to surgical procedures, preserving privacy, reducing healthcare costs, and eliminating surgical risks such as anesthesia complications or uterine perforation.Rapid Onset of Action: The medication demonstrates quick absorption and onset, with effects typically beginning within 30 minutes to two hours, allowing for predictable therapeutic outcomes.Cost-Effectiveness: Compared to surgical interventions or hospitalization for complications, MISOPIRATE 200 represents an economical treatment option, making essential healthcare more accessible to diverse populations.Versatile Clinical Applications: The medication's multiple therapeutic uses make it a valuable tool across different medical specialties, from gastroenterology to obstetrics.Stable Formulation: MISOPIRATE 200 maintains stability across various storage conditions, improving accessibility in regions with limited refrigeration infrastructure.Potential Side Effects and Adverse ReactionsWhile MISOPIRATE 200 is generally well-tolerated, users should be aware of possible side effects:Gastrointestinal Disturbances: Diarrhea occurs in approximately 15-40% of patients, typically mild and self-limiting. Abdominal cramping, nausea, and flatulence are also common, particularly during initial treatment phases.Uterine Effects: Women of reproductive age may experience menstrual irregularities, heavier menstrual flow, or intermenstrual spotting. Uterine cramping is expected when the medication is used for obstetric purposes.Vascular Symptoms: Some patients report headaches, dizziness, or hot flashes, though these are generally transient and mild in nature.Allergic Reactions: Though rare, hypersensitivity reactions including skin rashes, itching, or more serious anaphylactic responses can occur and require immediate medical attention.Serious Complications: When used inappropriately for pregnancy termination outside medical supervision, serious complications including incomplete abortion, severe bleeding, infection, or rupture can occur. This underscores the critical importance of medical oversight.Important Precautions and ContraindicationsMISOPIRATE 200 is absolutely contraindicated during pregnancy when the intention is to continue the pregnancy, as it can cause miscarriage or severe fetal abnormalities. Women of childbearing potential must use reliable contraception during treatment. The medication should not be used by individuals with known allergy to prostaglandins or those with inflammatory bowel disease without careful medical evaluation.Patients with cardiovascular disease, cerebrovascular conditions, or poorly controlled hypertension require careful monitoring when using MISOPIRATE 200. The medication may interact with antacids containing magnesium, potentially exacerbating diarrhea.Dosage and Administration GuidelinesDosing of MISOPIRATE 200 varies significantly based on the clinical indication. For gastric protection, typical regimens involve 200 mcg taken two to four times daily with meals. For obstetric uses, dosing protocols are highly specific and must be determined by qualified healthcare providers based on individual circumstances, gestational age, and medical history.The medication should be taken with food to minimize gastrointestinal side effects. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed otherwise by a healthcare provider.ConclusionMISOPIRATE 200 represents a significant therapeutic advancement in both gastroenterology and reproductive healthcare. Its dual capacity to protect the gastric mucosa and influence uterine function makes it an invaluable medication across multiple clinical scenarios. The proven efficacy in preventing NSAID-induced ulcers has prevented countless cases of serious gastrointestinal bleeding, while its role in women's healthcare has expanded access to safe, effective medical management options.", "price": 85.0, "discountamount": 25.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2287, "imageuri": "https://productimages.withfloats.com/actual/6979ab1bad683d72f6cf0b98.png", "tileimageuri": "https://productimages.withfloats.com/tile/6979ab1bad683d72f6cf0b98.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-01-28T06:22:13.304Z", "updatedon": "2026-01-28T12:41:00.351Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/misoprostol-tablet-200-mcg/2287", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "MISOPIRATE 200", "category": "GYANECOLOGYRANGE", "tags": [ "misoprostol tablet 200 mcg uses", "misoprostol 200 mcg tablet dosage", "misoprostol 200 mcg tablet benefits", "misoprostol tablet 200 mcg composition", "misoprostol 200 mcg tablet how it works", "misoprostol tablet 200 mcg side effects", "misoprostol 200 mcg tablet mechanism of action", "misoprostol tablet 200 mcg price in india", "misoprostol 200 mcg tablet storage instructions", "misoprostol 200 mcg tablet for gastric protection", "misoprostol 200 mcg tablet prostaglandin analog", "misoprostol tablet 200 mcg price in india", "misoprostol 200 mcg tablet administration guide", "misoprostol tablet 200 mcg patient information" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6961f2c52800555f6696ac8f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Sitagliptin Phosphate 100 mg", "description": "GLISITAPTIN 100 is a pharmaceutical formulation containing Sitagliptin Phosphate 100 mg as its active ingredient. This medication represents a significant advancement in the management of type 2 diabetes mellitus, offering patients an effective oral treatment option that works through an innovative mechanism of action. As part of the DPP-4 inhibitor class of antidiabetic medications, GLISITAPTIN 100 has emerged as a trusted choice for healthcare providers and patients seeking reliable glycemic control with a favorable safety profile.\nThe brand name GLISITAPTIN 100 signifies quality, efficacy, and a commitment to helping individuals with type 2 diabetes achieve better health outcomes. Each tablet is precisely formulated to deliver the optimal therapeutic dose of sitagliptin phosphate, ensuring consistent and predictable results in blood sugar management.\nUnderstanding Sitagliptin Phosphate\nSitagliptin phosphate is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that has revolutionized diabetes treatment since its introduction. Unlike older diabetes medications that work through insulin secretion or glucose absorption mechanisms alone, sitagliptin operates through the incretin system—a natural bodily process that regulates blood glucose levels in response to food intake.\nThe 100 mg strength available in GLISITAPTIN 100 represents the standard therapeutic dose for most adult patients, providing optimal efficacy while maintaining an excellent safety margin. This once-daily formulation simplifies treatment regimens and promotes better adherence, which is crucial for long-term diabetes management success.\nHow GLISITAPTIN 100 Works\nGLISITAPTIN 100 works through a sophisticated yet elegant mechanism that harnesses your body's natural glucose regulation system. When you eat, your intestines release hormones called incretins, specifically GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These incretins have multiple beneficial effects: they stimulate insulin secretion from the pancreas, suppress glucagon release (which reduces glucose production by the liver), and slow gastric emptying.\nHowever, these beneficial incretins are rapidly broken down by an enzyme called DPP-4, limiting their glucose-lowering effects. GLISITAPTIN 100 inhibits this DPP-4 enzyme, allowing incretins to remain active in your bloodstream for longer periods. This results in better insulin secretion when blood glucose is elevated, reduced glucagon levels, and ultimately improved blood sugar control throughout the day.\nImportantly, because this mechanism is glucose-dependent, GLISITAPTIN 100 primarily works when blood sugar is elevated, which significantly reduces the risk of hypoglycemia (dangerously low blood sugar) compared to some other diabetes medications.\nPrimary Uses and Indications\nType 2 Diabetes Mellitus Management: GLISITAPTIN 100 is primarily indicated for improving glycemic control in adult patients with type 2 diabetes mellitus. It can be prescribed as:\n\nMonotherapy: As a first-line treatment for patients who cannot achieve adequate control through diet and exercise alone, particularly when metformin is contraindicated or not tolerated\nCombination Therapy: Alongside metformin, sulfonylureas, thiazolidinediones, or insulin when these medications alone do not provide sufficient glucose control\nTriple Therapy: In combination with two other antidiabetic agents when dual therapy fails to achieve target HbA1c levels\n\nThe medication is particularly suitable for patients who require effective glucose control but have concerns about weight gain or hypoglycemia, as GLISITAPTIN 100 is weight-neutral and has a low hypoglycemia risk when used as monotherapy.\nKey Benefits of GLISITAPTIN 100\n1. Effective Glycemic Control\nClinical studies have demonstrated that GLISITAPTIN 100 significantly reduces HbA1c levels (a measure of long-term blood sugar control) by approximately 0.5-1.0%, helping patients achieve and maintain target glucose levels. This improvement translates to reduced risk of diabetes-related complications over time.\n2. Low Hypoglycemia Risk\nUnlike sulfonylureas or insulin, GLISITAPTIN 100 has a glucose-dependent mechanism, meaning it primarily works when blood sugar is elevated. This dramatically reduces the risk of hypoglycemic episodes, providing patients with greater safety and peace of mind, especially important for elderly patients or those with unpredictable meal schedules.\n3. Weight Neutral\nGLISITAPTIN 100 does not cause weight gain, a significant advantage over some other diabetes medications like insulin, sulfonylureas, or thiazolidinediones. Maintaining a healthy body weight is crucial for overall diabetes management and cardiovascular health.\n4. Once-Daily Convenience\nThe single daily dose requirement of GLISITAPTIN 100 simplifies treatment regimens, making it easier for patients to maintain adherence. Better adherence directly correlates with improved glycemic control and better long-term outcomes.\n5. Pancreatic Preservation\nBy working through the incretin system, GLISITAPTIN 100 may help preserve pancreatic beta-cell function, potentially slowing the progression of type 2 diabetes. This represents a significant long-term benefit beyond simple glucose control.\n6. Cardiovascular Safety\nClinical trials have demonstrated cardiovascular safety with sitagliptin, an important consideration given that cardiovascular disease is the leading cause of morbidity and mortality in patients with type 2 diabetes.\n7. Renal Dosing Available\nWhile the 100 mg dose is standard, sitagliptin can be adjusted for patients with kidney impairment, making it accessible to a broader patient population, including those with diabetic nephropathy.\n8. Well-Tolerated\nGLISITAPTIN 100 generally has a favorable side effect profile, with most patients experiencing minimal adverse effects, contributing to better quality of life during treatment.\nDosage and Administration\nThe standard recommended dose of GLISITAPTIN 100 is one tablet taken orally once daily, with or without food. The medication can be taken at any time of day, though taking it at the same time daily helps establish a routine and ensures consistent blood levels.\nFor patients with moderate to severe kidney disease, dosage adjustments may be necessary. Your healthcare provider will determine the appropriate dose based on your kidney function tests. It's crucial to follow your doctor's instructions precisely and not adjust your dose without medical guidance.\nPotential Side Effects\nWhile GLISITAPTIN 100 is generally well-tolerated, like all medications, it may cause side effects in some individuals:\nCommon Side Effects (Affecting 1-10% of patients):\n\nUpper respiratory tract infections\nNasopharyngitis (common cold symptoms)\nHeadache\nNausea\nAbdominal pain\nDiarrhea\n\nThese side effects are typically mild and often resolve on their own as your body adjusts to the medication.\nLess Common but Serious Side Effects:\n\nPancreatitis: Severe abdominal pain that may radiate to the back, with or without vomiting, requires immediate medical attention\nSevere Joint Pain: Persistent, severe joint pain has been reported in some patients; inform your doctor if this occurs\nAllergic Reactions: Rare cases of serious allergic reactions including anaphylaxis, angioedema, and severe skin reactions have occurred\nHeart Failure: In patients with existing heart disease, worsening heart failure has been reported\nBullous Pemphigoid: A rare skin condition requiring discontinuation of the medication\n\nWhen Used with Other Diabetes Medications:\nWhen GLISITAPTIN 100 is combined with sulfonylureas or insulin, the risk of hypoglycemia increases. Your doctor may reduce the dose of these medications when adding GLISITAPTIN 100 to your regimen.\nPrecautions and Contraindications\nDo Not Use GLISITAPTIN 100 if:\n\nYou are allergic to sitagliptin or any ingredients in the formulation\nYou have type 1 diabetes or diabetic ketoacidosis\nYou are under 18 years of age (safety and efficacy not established)\n\nUse with Caution if:\n\nYou have a history of pancreatitis\nYou have kidney disease (dose adjustment required)\nYou have heart failure\nYou are pregnant or planning to become pregnant\nYou are breastfeeding\n\nImportant Patient Information\nMonitoring: Regular monitoring of blood glucose levels and HbA1c testing (typically every 3-6 months) is essential to assess treatment effectiveness and make necessary adjustments.\nLifestyle Factors: GLISITAPTIN 100 works best when combined with a healthy diet, regular physical activity, and weight management. Medication alone cannot substitute for comprehensive lifestyle management.\nMissed Dose: If you miss a dose, take it as soon as you remember on the same day. If it's almost time for your next dose, skip the missed dose and continue with your regular schedule. Never double up doses.\nStorage: Store GLISITAPTIN 100 at room temperature, away from moisture and heat. Keep the medication in its original container and out of reach of children.\nDrug Interactions\nGLISITAPTIN 100 has few significant drug interactions, contributing to its safety profile. However, inform your healthcare provider about all medications, supplements, and herbal products you're taking. Particular attention should be paid to:\n\nOther diabetes medications (may require dose adjustments)\nDigoxin (levels may be slightly increased)\nMedications affecting kidney function\n\nConclusion\nGLISITAPTIN 100 (Sitagliptin Phosphate 100 mg) represents a modern, effective, and well-tolerated option for managing type 2 diabetes mellitus. Its innovative mechanism through the incretin system offers multiple advantages including effective glucose control, low hypoglycemia risk, weight neutrality, and once-daily convenience. These benefits make it an excellent choice for many patients, whether used alone or in combination with other antidiabetic medications.", "price": 464.0, "discountamount": 139.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2272, "imageuri": "https://productimages.withfloats.com/actual/6961f2c8ba33389b8e9f0122.png", "tileimageuri": "https://productimages.withfloats.com/tile/6961f2c8ba33389b8e9f0122.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-01-10T06:33:41.727Z", "updatedon": "2026-02-12T09:52:37.325Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/sitagliptin-phosphate-100-mg/2272", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLISITAPTIN 100", "category": "DIABETIC RANGE", "tags": [ "sitagliptin phosphate 100 mg tablet uses", "sitagliptin phosphate 100 mg dosage", "sitagliptin phosphate 100 mg side effects", "sitagliptin phosphate 100 mg benefits", "sitagliptin phosphate 100 mg price in india", "sitagliptin phosphate tablets 100 mg", "what is sitagliptin phosphate 100 mg used for", "how sitagliptin phosphate works in diabetes", "sitagliptin phosphate 100 mg for type 2 diabetes", "sitagliptin phosphate 100 mg mechanism of action", "sitagliptin phosphate tablet how to take", "medicine to control blood sugar sitagliptin", "tablet for post meal blood sugar control", "sitagliptin phosphate for high blood sugar", "can sitagliptin phosphate cause weight gain" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6960c83f3056ad8a5a1aecba", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Cinnarizine and Domperidone Tablets ", "description": "CLANARIZINE DOM represents an advanced pharmaceutical combination that brings together two potent therapeutic agents—Cinnarizine and Domperidone—in a single convenient tablet formulation. This innovative combination medication addresses multiple aspects of vestibular disorders, motion sickness, and associated nausea and vomiting, providing comprehensive relief for patients suffering from these debilitating conditions. Manufactured under stringent quality control standards, CLANARIZINE DOM offers a synergistic approach to managing symptoms that significantly impact quality of life and daily functioning.The combination of Cinnarizine and Domperidone in CLANARIZINE DOM is based on sound pharmacological principles. While Cinnarizine works primarily on the vestibular system to reduce dizziness and vertigo, Domperidone acts as an effective antiemetic to control nausea and vomiting. Together, these two active ingredients provide more comprehensive symptom control than either agent alone, making CLANARIZINE DOM an excellent choice for patients experiencing vestibular disturbances accompanied by gastrointestinal symptoms.This combination therapy is particularly valuable because vertigo, dizziness, and motion sickness are frequently accompanied by nausea and vomiting. Patients suffering from these conditions often find that addressing only one aspect of their symptoms provides insufficient relief. CLANARIZINE DOM's dual-action formula tackles both the underlying vestibular dysfunction and the accompanying gastrointestinal distress, offering patients a more complete therapeutic solution that improves both comfort and functional capacity.Understanding the Active IngredientsCinnarizine is a calcium channel blocker with specific antihistaminic and vestibular suppressant properties. Unlike systemic calcium channel blockers used for cardiovascular conditions, Cinnarizine selectively acts on the blood vessels in the inner ear and brain, improving blood flow to these areas. This enhanced circulation helps reduce the frequency and severity of vertigo attacks while also preventing motion sickness. Cinnarizine also possesses mild antihistaminic effects that contribute to its anti-nausea properties, though this is not its primary mechanism of action.The medication works by blocking calcium channels in the vestibular system, which helps stabilize the sensory organs responsible for balance. By reducing the excessive stimulation of the vestibular apparatus, Cinnarizine decreases the sensation of spinning or imbalance that characterizes vertigo. Additionally, its vasodilatory effects improve microcirculation in the inner ear, which can be beneficial for conditions where reduced blood flow contributes to symptoms.Domperidone is a peripheral dopamine antagonist that acts primarily as a prokinetic and antiemetic agent. Unlike some antiemetic medications that cross the blood-brain barrier and cause sedation or extrapyramidal side effects, Domperidone works predominantly in the peripheral nervous system. It blocks dopamine receptors in the chemoreceptor trigger zone (CTZ) located outside the blood-brain barrier, effectively preventing nausea and vomiting without causing significant central nervous system effects.Domperidone also enhances gastrointestinal motility by promoting coordinated contractions of the stomach and upper small intestine. This prokinetic effect helps empty the stomach more efficiently, reducing feelings of fullness, bloating, and discomfort that often accompany vestibular disorders. By accelerating gastric emptying, Domperidone also reduces the likelihood of gastroesophageal reflux, which can exacerbate nausea in some patients.The combination of these two medications in CLANARIZINE DOM creates a complementary therapeutic effect. While Cinnarizine addresses the vestibular component of dizziness and vertigo, Domperidone manages the gastrointestinal symptoms that frequently accompany these conditions. This dual approach provides more comprehensive symptom relief and improves overall treatment outcomes compared to monotherapy with either agent alone.Clinical Applications and UsesCLANARIZINE DOM is indicated for a wide range of conditions characterized by vertigo, dizziness, and associated nausea. Understanding these clinical applications helps healthcare providers select appropriate candidates for this combination therapy.Vestibular Disorders: The primary indication for CLANARIZINE DOM includes various vestibular disorders that cause vertigo and imbalance. These conditions include Ménière's disease, benign paroxysmal positional vertigo (BPPV), vestibular neuritis, and labyrinthitis. Patients with these disorders experience episodes of spinning sensation, loss of balance, and often severe nausea. CLANARIZINE DOM helps reduce the frequency and intensity of vertigo attacks while controlling the accompanying gastrointestinal symptoms.Motion Sickness: CLANARIZINE DOM is highly effective for preventing and treating motion sickness, whether related to travel by car, boat, airplane, or amusement park rides. The medication can be taken prophylactically before travel or at the onset of symptoms. The combination is particularly useful for individuals who experience severe nausea and vomiting with motion sickness, as Domperidone provides powerful antiemetic effects that complement Cinnarizine's anti-motion-sickness properties.Migraine-Associated Vertigo: Many patients with migraines experience vestibular symptoms, including dizziness, vertigo, and motion sensitivity, either during migraine attacks or as independent episodes. CLANARIZINE DOM can help manage these vestibular manifestations of migraine, reducing both the vertigo and the nausea that often accompany migraine headaches.Post-Concussion Syndrome: Following head injuries, some patients develop persistent dizziness, balance problems, and nausea as part of post-concussion syndrome. CLANARIZINE DOM may provide symptomatic relief for these patients during their recovery period, though it should be used as part of a comprehensive treatment approach that includes rest, gradual return to activities, and vestibular rehabilitation when appropriate.Cerebrovascular Insufficiency: In older adults with reduced blood flow to the brain, symptoms such as dizziness, vertigo, tinnitus (ringing in the ears), and cognitive difficulties may develop. Cinnarizine's vasodilatory properties can improve cerebral circulation, potentially reducing these symptoms. The addition of Domperidone helps manage any associated nausea.Radiation-Induced or Chemotherapy-Induced Nausea: While not a primary indication, some healthcare providers use CLANARIZINE DOM as adjunctive therapy for patients undergoing cancer treatment who experience both nausea and dizziness. Domperidone's strong antiemetic properties are particularly valuable in this context.Key Benefits of CLANARIZINE DOMThe unique combination of Cinnarizine and Domperidone in CLANARIZINE DOM offers numerous advantages that make it a preferred choice for managing vestibular disorders and associated symptoms.Comprehensive Symptom Control: The primary benefit of CLANARIZINE DOM is its ability to address multiple symptoms simultaneously. Rather than requiring patients to take separate medications for vertigo and nausea, this combination provides unified treatment in a single tablet. This comprehensive approach improves symptom control across the full spectrum of vestibular disorder manifestations, from the spinning sensation to the gastrointestinal distress that often accompanies it.Improved Patient Compliance: Taking multiple medications can be burdensome, particularly for patients who feel dizzy or nauseated. CLANARIZINE DOM simplifies the treatment regimen by combining two medications in one tablet, making it easier for patients to adhere to their prescribed therapy. Better compliance translates to better outcomes, as consistent medication use is essential for managing chronic vestibular conditions.Synergistic Therapeutic Effects: The combination of Cinnarizine and Domperidone creates synergistic effects that enhance overall efficacy. While Cinnarizine reduces vestibular stimulation and improves inner ear blood flow, Domperidone prevents nausea and promotes gastric emptying. This dual action addresses both the cause and consequences of vestibular dysfunction, providing more complete relief than either medication alone.Reduced Central Nervous System Side Effects: Because Domperidone works primarily in the peripheral nervous system rather than crossing the blood-brain barrier extensively, CLANARIZINE DOM causes less sedation and fewer cognitive effects compared to some alternative antiemetic medications. This allows patients to maintain better alertness and function during treatment, which is particularly important for those who need to continue working or performing daily activities.Enhanced Quality of Life: Vertigo and chronic dizziness significantly impair quality of life, limiting mobility, social interactions, and occupational functioning. The nausea and vomiting that accompany these conditions add another layer of disability. By effectively controlling both vestibular and gastrointestinal symptoms, CLANARIZINE DOM helps restore patients' ability to engage in normal activities, improving overall life satisfaction and functional independence.Fast Onset of Action: CLANARIZINE DOM provides relatively rapid symptom relief, with many patients experiencing improvement within 30 minutes to 2 hours after taking the medication. This quick onset is particularly valuable for acute episodes of vertigo or when taking the medication prophylactically before situations that might trigger motion sickness.Suitable for Long-Term Use: For patients with chronic vestibular disorders requiring ongoing treatment, CLANARIZINE DOM is generally safe for extended use when properly monitored by a healthcare provider. The medication maintains its effectiveness over time without significant tolerance development, making it suitable for long-term symptom management.Improved Gastric Emptying: The prokinetic effects of Domperidone benefit not only nausea but also other gastrointestinal symptoms such as early satiety, bloating, and upper abdominal discomfort. Patients with vestibular disorders often develop gastroparesis or delayed gastric emptying secondary to their condition, and Domperidone addresses this issue effectively.Vascular Benefits: Cinnarizine's ability to improve blood flow to the inner ear and brain provides additional benefits beyond symptom control. Enhanced microcirculation may support healing and recovery in conditions where vascular insufficiency contributes to vestibular dysfunction.Side Effects and Safety ConsiderationsLike all medications, CLANARIZINE DOM can cause side effects, though not everyone experiences them. Understanding potential adverse effects helps patients recognize when to seek medical attention and allows healthcare providers to monitor therapy appropriately.Common Side Effects:The most frequently reported side effect of CLANARIZINE DOM is drowsiness or sedation, occurring in approximately 10-20% of patients. This effect is primarily attributable to Cinnarizine's antihistaminic properties. Patients should avoid driving or operating machinery until they know how the medication affects them. Taking the medication at bedtime can minimize daytime drowsiness for some patients.Dry mouth is another common side effect, affecting roughly 10-15% of patients. This occurs due to anticholinergic effects and can be managed by sipping water frequently, chewing sugar-free gum, or using saliva substitutes if severe. Maintaining good oral hygiene is important to prevent dental problems associated with reduced saliva production.Mild gastrointestinal symptoms, including constipation, abdominal discomfort, or changes in bowel habits, may occur. While Domperidone promotes gastric emptying, it can occasionally alter bowel motility. These effects are usually mild and resolve with continued use or dose adjustment.", "price": 55.0, "discountamount": 17.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2271, "imageuri": "https://productimages.withfloats.com/actual/6960c8410b0da405bc908e58.png", "tileimageuri": "https://productimages.withfloats.com/tile/6960c8410b0da405bc908e58.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-01-09T09:19:59.281Z", "updatedon": "2026-01-09T09:19:59.281Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/cinnarizine-and-domperidone-tablets-/2271", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CLANARIZINE DOM", "category": "NEUROLOGY RANGE", "tags": [ "cinnarizine and domperidone tablet uses", "what is cinnarizine & domperidone tablet used for", "cinnarizine domperidone combination medicine benefits", "how cinnarizine domperidone tablet works", "cinnarizine domperidone tablet for vertigo treatment", "cinnarizine domperidone tablet for inner ear problem", "cinnarizine domperidone tablet for balance disorder", "cinnarizine domperidone tablet for travel sickness", "cinnarizine domperidone tablet for gastric nausea", "cinnarizine & domperidone tablet price in india", "cinnarizine domperidone tablet brand name", "cinnarizine domperidone tablet manufacturer in india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "695b65af2800555f6696a6cf", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Cinacalcet 60 mg Tablet", "description": "CINASELECT 60: Comprehensive Guide to Cinacalcet 60 mg Tablets\nProduct Overview\nCINASELECT 60 is a pharmaceutical formulation containing Cinacalcet hydrochloride 60 mg as its active ingredient. This medication represents a significant advancement in the management of calcium metabolism disorders, particularly in patients with chronic kidney disease and parathyroid conditions. As a calcimimetic agent, CINASELECT 60 works by mimicking the action of calcium on tissues, helping to restore hormonal balance and mineral homeostasis in the body.\nThe 60 mg dosage strength offers an effective therapeutic option for patients requiring moderate to higher-level intervention in managing parathyroid hormone levels and associated calcium imbalances. CINASELECT 60 is manufactured under strict quality control standards, ensuring consistency, purity, and efficacy in every tablet.\nUnderstanding How CINASELECT 60 Works\nCINASELECT 60 operates through a sophisticated mechanism that targets the calcium-sensing receptors located on the surface of parathyroid gland cells. These receptors play a crucial role in regulating parathyroid hormone secretion, which in turn controls calcium and phosphorus levels in the bloodstream.\nWhen you take CINASELECT 60, the active ingredient cinacalcet binds to these calcium-sensing receptors, increasing their sensitivity to extracellular calcium. This enhanced sensitivity tricks the parathyroid glands into “thinking” there is more calcium present in the blood than there actually is. As a result, the glands reduce their production and release of parathyroid hormone (PTH).\nBy lowering PTH levels, CINASELECT 60 subsequently reduces calcium levels in the blood and decreases the amount of phosphorus absorbed from the intestines. This cascade effect helps restore the delicate mineral balance that is often disrupted in patients with kidney disease or parathyroid disorders.\nPrimary Therapeutic Uses\nSecondary Hyperparathyroidism in Chronic Kidney Disease\nThe primary indication for CINASELECT 60 is the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) who are on dialysis. When kidneys fail to function properly, they cannot adequately regulate calcium and phosphorus levels, leading to excessive parathyroid hormone production. This condition can result in serious complications including bone disease, cardiovascular calcification, and increased mortality risk.\nCINASELECT 60 helps manage this condition by controlling PTH levels, thereby reducing the risk of bone complications such as osteitis fibrosa cystica and preventing the dangerous deposition of calcium in blood vessels and soft tissues.\nHypercalcemia in Parathyroid Carcinoma\nCINASELECT 60 is also indicated for treating hypercalcemia (elevated blood calcium levels) in patients with parathyroid carcinoma, a rare malignant tumor of the parathyroid glands. In these cases, the medication helps control the dangerously high calcium levels that can lead to kidney stones, bone pain, digestive issues, and neurological symptoms.\nPrimary Hyperparathyroidism\nFor patients with severe hypercalcemia due to primary hyperparathyroidism who cannot undergo parathyroidectomy or for whom surgery has failed, CINASELECT 60 offers a valuable medical management option. This provides relief for patients who are not surgical candidates due to advanced age, comorbidities, or other contraindications.\nKey Benefits of CINASELECT 60\nEffective PTH Control\nClinical studies have demonstrated that CINASELECT 60 significantly reduces parathyroid hormone levels in a dose-dependent manner. This reduction helps prevent the cascade of complications associated with elevated PTH, including bone mineral loss and cardiovascular calcification.\nImproved Calcium-Phosphorus Balance\nBy reducing PTH secretion, CINASELECT 60 helps normalize serum calcium and phosphorus levels. This is particularly important in dialysis patients, where mineral imbalances can lead to serious complications affecting bone health, cardiovascular function, and overall quality of life.\nReduced Cardiovascular Risk\nElevated calcium and phosphorus levels contribute to vascular calcification, a major risk factor for cardiovascular disease in patients with chronic kidney disease. By managing these mineral levels, CINASELECT 60 may help reduce the risk of cardiovascular complications, which are the leading cause of death in dialysis patients.\nBone Health Preservation\nUncontrolled secondary hyperparathyroidism leads to renal osteodystrophy, a condition characterized by abnormal bone metabolism. CINASELECT 60 helps protect bone integrity by normalizing PTH levels, potentially reducing fracture risk and preserving bone mineral density.\nAlternative to Surgery\nFor patients with primary hyperparathyroidism or parathyroid carcinoma who cannot undergo surgery, CINASELECT 60 provides an effective medical management option. This is particularly valuable for elderly patients or those with multiple comorbidities that make surgery risky.\nQuality of Life Improvement\nBy controlling symptoms associated with hypercalcemia and hyperparathyroidism, such as bone pain, muscle weakness, fatigue, and digestive issues, CINASELECT 60 can significantly improve patients' overall quality of life and functional capacity.\nConvenient Oral Administration\nCINASELECT 60 is administered orally, making it more convenient than injectable alternatives. This allows for outpatient management and reduces the burden on healthcare facilities and patients.\nPotential Side Effects and Adverse Reactions\nCommon Side Effects\nPatients taking CINASELECT 60 may experience several common side effects, which typically include nausea and vomiting, occurring in approximately 20-30% of patients. These gastrointestinal symptoms are usually mild to moderate and may improve over time as the body adjusts to the medication.\nDiarrhea is another frequent complaint, affecting roughly 20% of users. Some patients also report muscle pain or myalgia, dizziness, loss of appetite, and asthenia (general weakness or fatigue).\nSerious Side Effects Requiring Medical Attention\nHypocalcemia: The most significant risk associated with CINASELECT 60 is the development of low calcium levels in the blood. Severe hypocalcemia can lead to paresthesias (tingling sensations), muscle cramps or spasms, tetany, seizures, and QT interval prolongation on electrocardiogram, which can predispose to dangerous heart rhythm abnormalities.\nGastrointestinal Bleeding: There have been reports of gastrointestinal hemorrhage in patients taking cinacalcet, particularly in those with risk factors such as gastritis, ulcers, or concurrent use of other medications that increase bleeding risk.\nAdynamic Bone Disease: Oversuppression of PTH can lead to adynamic bone disease, a condition where bone turnover becomes abnormally low, potentially weakening bones despite normalized calcium levels.\nCardiovascular Effects: Some patients may experience worsening heart failure or arrhythmias, particularly if hypocalcemia develops. Close monitoring is essential in patients with underlying cardiovascular disease.\nAllergic Reactions: Though rare, hypersensitivity reactions including rash, urticaria, and angioedema have been reported.\nPrecautions and Contraindications\nCINASELECT 60 should not be used in patients with serum calcium levels below the normal range. It requires careful dose adjustment and monitoring in patients with hepatic impairment. The medication may interact with drugs metabolized by the CYP2D6 enzyme system and with medications that affect gastric pH.\nPregnant or breastfeeding women should use CINASELECT 60 only if clearly needed, as its safety in these populations has not been fully established. Regular monitoring of serum calcium, phosphorus, and PTH levels is essential throughout treatment.\nDosage and Administration Guidelines\nCINASELECT 60 should be taken orally with food or shortly after a meal, as this improves absorption and reduces gastrointestinal side effects. Tablets should be swallowed whole and not crushed, chewed, or divided.\nThe typical starting dose for secondary hyperparathyroidism is lower than 60 mg, with gradual titration based on PTH and calcium levels. The 60 mg strength is often used as part of the dose escalation process or as a maintenance dose once optimal PTH control is achieved.\nDose adjustments should be made no more frequently than every two to four weeks, as it takes this long to see the full effect of a dose change on PTH levels. Treatment should be individualized based on laboratory values and clinical response.\nMonitoring Requirements\nPatients on CINASELECT 60 require regular monitoring of serum calcium, phosphorus, and intact PTH levels. Calcium levels should be checked within one week of starting treatment or after any dose adjustment, and then monthly once stable. PTH levels should be measured one to four weeks after initiation or dose adjustment, then every one to three months during maintenance therapy.\nAdditionally, patients should be monitored for signs and symptoms of hypocalcemia, particularly during the initial treatment period. Electrocardiogram monitoring may be appropriate in patients at risk for QT prolongation.\nStorage and Handling\nCINASELECT 60 should be stored at room temperature, away from moisture and direct sunlight. The medication should be kept in its original container with the lid tightly closed to protect from humidity. Keep out of reach of children and pets. Do not use past the expiration date printed on the package.\nConclusion\nCINASELECT 60 (Cinacalcet 60 mg) represents a valuable therapeutic option in the management of secondary hyperparathyroidism associated with chronic kidney disease, hypercalcemia in parathyroid carcinoma, and primary hyperparathyroidism in patients who cannot undergo surgery. Its unique mechanism as a calcimimetic agent provides effective control of parathyroid hormone secretion, helping to restore mineral balance and prevent serious complications.\nThe benefits of CINASELECT 60 extend beyond simple laboratory value normalization. By controlling PTH, calcium, and phosphorus levels, this medication helps preserve bone health, reduce cardiovascular calcification risk, and improve overall quality of life for patients dealing with complex metabolic disorders. For patients who are not surgical candidates, CINASELECT 60 offers hope and effective symptom management.\nHowever, like all medications, CINASELECT 60 must be used judiciously under close medical supervision. The risk of hypocalcemia and other potential side effects necessitates regular laboratory monitoring and open communication between patients and healthcare providers. Patients should report any concerning symptoms promptly and attend all scheduled follow-up appointments.", "price": 740.0, "discountamount": 222.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2266, "imageuri": "https://productimages.withfloats.com/actual/695b65ebf30763183f64d4f7.png", "tileimageuri": "https://productimages.withfloats.com/tile/695b65ebf30763183f64d4f7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2026-01-05T07:18:07.264Z", "updatedon": "2026-01-05T11:40:04.861Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/cinacalcet-60-mg-tablet/2266", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CINASELECT 60", "category": "NEPHROLOGYRANGE", "tags": [ "cinacalcet 60 mg", "cinacalcet 60 mg tablet", "cinacalcet 60 mg price", "cinacalcet 60 mg tab", "cinacalcet mechanism of action.", "cinacalcet uses", "tab cinacalcet.", "cinacalcet dose.", "cinacalcet structure.", "cinacalcet tab.", "calcium and phosphorus levels in the bloodstream.", "parathyroid hormone secretion.", "calcium metabolism disorders.", "chronic kidney disease and parathyroid conditions." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694d181a5837f90c86a7e9f9", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Frusemide IP 40mg ", "description": "FRUSIP 40 is a pharmaceutical formulation containing Frusemide IP 40mg as its active ingredient, presented in tablet form for oral administration. This medication belongs to the class of loop diuretics, which are among the most potent diuretic agents available in modern medicine. FRUSIP 40 is specifically designed to help manage conditions associated with fluid retention and elevated blood pressure, offering patients a reliable therapeutic solution for maintaining optimal fluid balance in the body.\nThe formulation adheres to Indian Pharmacopoeia (IP) standards, ensuring consistent quality, purity, and efficacy. Each tablet is precisely manufactured to deliver the exact dosage required for effective treatment while maintaining the highest safety standards in pharmaceutical production.\nUnderstanding Furosemide and Its Mechanism\nFrusemide, also known as furosemide in some regions, is a powerful loop diuretic that works primarily in the kidneys. The medication exerts its therapeutic effect by inhibiting the reabsorption of sodium and chloride in the ascending loop of Henle, a specific segment of the kidney's nephron. This action prevents the body from retaining excess salt and water, leading to increased urine production and the subsequent elimination of accumulated fluids.\nThe “loop” designation comes from the specific site of action within the kidney's loop of Henle, making frusemide significantly more potent than thiazide diuretics that work in different parts of the kidney. This enhanced potency makes FRUSIP 40 particularly valuable in managing conditions requiring substantial fluid removal.\nPrimary Uses and Indications\nFRUSIP 40 is prescribed for various medical conditions where fluid accumulation poses health risks or causes discomfort:\nEdema Management: The medication is highly effective in treating edema (swelling) associated with congestive heart failure, where the heart's reduced pumping efficiency leads to fluid buildup in the lungs, legs, and other tissues. It helps alleviate breathing difficulties and reduces the strain on the cardiovascular system.\nLiver Disease: Patients with cirrhosis or other liver conditions often develop ascites, an accumulation of fluid in the abdominal cavity. FRUSIP 40 helps manage this uncomfortable and potentially dangerous condition by promoting fluid elimination.\nKidney Disorders: In cases of nephrotic syndrome and other renal conditions causing fluid retention, this medication assists in maintaining proper fluid balance, though it must be used judiciously under medical supervision in patients with compromised kidney function.\nHypertension Control: FRUSIP 40 serves as an effective antihypertensive agent, helping to lower blood pressure by reducing blood volume through increased fluid excretion. This is particularly beneficial for patients whose hypertension is resistant to other treatments.\nPulmonary Edema: In acute situations where fluid accumulates in the lungs, this medication can provide rapid relief, making it a valuable tool in emergency medical settings.\nKey Benefits and Therapeutic Advantages\nThe advantages of FRUSIP 40 extend beyond its primary diuretic function, offering patients multiple therapeutic benefits:\nRapid Onset of Action: One of the most significant advantages is the quick response time. Patients typically experience diuretic effects within 30 to 60 minutes of oral administration, with peak effects occurring within one to two hours. This rapid action is particularly valuable in acute situations requiring prompt fluid removal.\nPotent Efficacy: As a loop diuretic, FRUSIP 40 demonstrates superior diuretic potency compared to thiazide diuretics, making it the preferred choice for patients with severe fluid retention or those who haven't responded adequately to milder diuretics.\nCardiovascular Protection: By reducing fluid overload, the medication decreases the workload on the heart, helping to prevent complications in patients with heart failure. This protective effect can significantly improve quality of life and potentially reduce hospitalizations.\nSymptom Relief: Patients often experience notable improvement in symptoms such as shortness of breath, swelling in the extremities, and abdominal distension. This symptomatic relief contributes to enhanced mobility and daily functioning.\nFlexible Dosing: The 40mg strength allows healthcare providers to adjust treatment according to individual patient needs, either maintaining this dose or modifying it based on therapeutic response and tolerance.\nElectrolyte Management: When used under proper medical supervision with appropriate monitoring, the medication allows for controlled fluid management while maintaining awareness of electrolyte balance.\nPotential Side Effects and Considerations\nWhile FRUSIP 40 is generally well-tolerated, patients should be aware of potential side effects:\nCommon Side Effects: These include increased urination frequency (which is expected), dizziness or lightheadedness upon standing (due to reduced blood volume), muscle cramps, and mild headaches. These effects often diminish as the body adjusts to the medication.\nElectrolyte Imbalances: The medication can cause depletion of important electrolytes, including potassium, sodium, magnesium, and calcium. Symptoms may include weakness, irregular heartbeat, confusion, or severe muscle cramps. Regular monitoring through blood tests is essential.\nDehydration Risk: Excessive fluid loss can lead to dehydration, characterized by extreme thirst, dry mouth, decreased urine output, and confusion. Patients must maintain adequate fluid intake as directed by their healthcare provider.\nMetabolic Effects: Some patients may experience increased blood sugar levels, elevated uric acid (potentially triggering gout attacks), or changes in cholesterol levels.\nHearing Changes: Rarely, particularly at higher doses, patients may experience ringing in the ears (tinnitus) or temporary hearing impairment.\nPhotosensitivity: Increased sensitivity to sunlight may occur, requiring appropriate sun protection measures.\nDrug Interactions: FRUSIP 40 can interact with numerous medications, including certain antibiotics, other blood pressure medications, NSAIDs, and lithium, necessitating comprehensive medication review by healthcare providers.\nImportant Safety Information\nPatients taking FRUSIP 40 should inform their healthcare provider about any existing medical conditions, particularly kidney disease, liver disease, diabetes, gout, or lupus. Pregnant and breastfeeding women require special consideration, as the medication crosses the placenta and appears in breast milk.\nRegular monitoring of kidney function, electrolyte levels, and blood pressure is essential for safe and effective therapy. Patients should maintain consistent communication with their healthcare team and report any unusual symptoms promptly.\nConclusion\nFRUSIP 40 (Frusemide IP 40mg Tablets) represents a cornerstone therapy in the management of conditions involving fluid retention and hypertension. Its potent diuretic action, rapid onset, and proven efficacy make it an invaluable tool in cardiovascular and renal medicine. The medication offers significant benefits in symptom relief, cardiovascular protection, and overall quality of life improvement for patients struggling with edema and related conditions.\nHowever, the power of this medication demands respect and proper medical supervision. The potential for electrolyte imbalances and other side effects necessitates regular monitoring and open communication between patients and healthcare providers. When used appropriately under medical guidance, with proper monitoring and patient education, FRUSIP 40 can dramatically improve patient outcomes and help individuals regain control over conditions that significantly impact their daily lives.\nPatients prescribed FRUSIP 40 should view this medication as part of a comprehensive treatment plan that may include dietary modifications, lifestyle changes, and other medications. Success with this therapy depends on adherence to prescribed dosing, regular follow-up appointments, and proactive management of potential side effects. With proper use, FRUSIP 40 continues to serve as a trusted and effective therapeutic option for millions of patients worldwide requiring diuretic therapy.", "price": 14.0, "discountamount": 5.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2255, "imageuri": "https://productimages.withfloats.com/actual/694d1821ad363997d8b04dfb.png", "tileimageuri": "https://productimages.withfloats.com/tile/694d1821ad363997d8b04dfb.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-25T10:55:22.405Z", "updatedon": "2025-12-29T06:00:01.971Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/frusemide-ip-40mg-/2255", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "FRUSIP 40", "category": "UROLOGYRANGE", "tags": [ "FRUSIP 40", "blood pressure", "blood pressure control", "It helps alleviate breathing difficulties and reduces the strain on the cardiovascular system.", "fluid buildup in the lungs, legs, and other tissues.", "kidney's loop of Henle, making frusemide significantly more potent than thiazide diuretics that work in different parts of the kidney.", "Metabolic Effects." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694d14f6274fc8b97e9b7120", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Mirtazapine 30mg", "description": "MIRTAZPRIME 30 is a pharmaceutical formulation containing Mirtazapine 30mg as per Indian Pharmacopoeia (IP) standards. This prescription medication belongs to a class of drugs known as tetracyclic antidepressants and represents an advanced therapeutic option for individuals struggling with major depressive disorder and related mental health conditions. Manufactured under stringent quality control measures, MIRTAZPRIME 30 offers patients a reliable and effective solution for managing depression while also addressing associated symptoms such as insomnia and anxiety.\nMirtazapine, the active pharmaceutical ingredient in MIRTAZPRIME 30, works through a unique dual mechanism that distinguishes it from other antidepressants. Unlike selective serotonin reuptake inhibitors (SSRIs), mirtazapine enhances the release of both norepinephrine and serotonin in the brain by blocking specific receptors. This innovative approach not only helps alleviate depressive symptoms but also provides sedative effects that can be particularly beneficial for patients experiencing sleep disturbances alongside depression.\nTherapeutic Uses and Applications\nMIRTAZPRIME 30 is primarily indicated for the treatment of major depressive disorder (MDD), a serious mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in daily activities. The medication has demonstrated significant efficacy in clinical trials, showing improvement in mood, energy levels, and overall quality of life for patients suffering from depression.\nBeyond its primary indication, healthcare providers may prescribe MIRTAZPRIME 30 for various off-label uses based on clinical judgment and patient needs. The medication has shown promise in managing generalized anxiety disorder, where excessive worry and tension interfere with daily functioning. Its sedative properties make it particularly valuable for patients experiencing insomnia related to depression or anxiety, as it can help restore healthy sleep patterns without the need for additional sleep medications.\nThe 30mg dosage strength represents a therapeutic level commonly prescribed for maintenance treatment after initial dose titration. Patients typically begin with lower doses and gradually increase to 30mg as their body adjusts to the medication and their symptoms require more robust management. This dosage provides an optimal balance between therapeutic efficacy and side effect management for many individuals.\nMIRTAZPRIME 30 may also be considered for patients who have not responded adequately to other antidepressant therapies, offering an alternative mechanism of action that can break through treatment-resistant depression. Additionally, its appetite-stimulating effects can be beneficial for patients experiencing significant weight loss due to depression or other medical conditions.\nKey Benefits and Therapeutic Advantages\nThe benefits of MIRTAZPRIME 30 extend beyond simple symptom relief, offering patients a multifaceted approach to mental health recovery. One of the most significant advantages is its relatively rapid onset of action compared to many other antidepressants. While most SSRIs require several weeks to demonstrate meaningful clinical improvement, patients taking mirtazapine often experience some relief from symptoms within one to two weeks, with continued improvement over subsequent weeks.\nThe dual neurotransmitter action of MIRTAZPRIME 30 provides comprehensive coverage of depressive symptoms. By enhancing both serotonergic and noradrenergic neurotransmission, the medication addresses the complex neurochemical imbalances underlying depression more thoroughly than single-mechanism antidepressants. This broader action can result in more complete symptom resolution and better overall outcomes.\nSleep improvement represents another crucial benefit of MIRTAZPRIME 30. The medication's sedative properties, particularly pronounced at lower doses, help patients fall asleep faster and enjoy more restorative sleep throughout the night. This is especially valuable since sleep disturbances are both a symptom and an exacerbating factor in depression. Better sleep quality contributes to improved daytime functioning, energy levels, and emotional regulation.\nUnlike many antidepressants that commonly cause sexual dysfunction, MIRTAZPRIME 30 has a relatively favorable profile in this regard. The medication is less likely to interfere with sexual function, making it an attractive option for patients who have experienced these troublesome side effects with other antidepressants. This characteristic can significantly improve treatment adherence and quality of life.\nThe appetite-stimulating effect, while considered a side effect by some, can be therapeutically beneficial for patients experiencing significant weight loss or poor appetite due to depression. MIRTAZPRIME 30 can help restore healthy eating patterns and reverse the physical decline that often accompanies severe depressive episodes.\nFurthermore, MIRTAZPRIME 30 does not typically cause the gastrointestinal side effects commonly associated with SSRI antidepressants, such as nausea, diarrhea, or stomach upset. This improved gastrointestinal tolerability enhances patient comfort and compliance with treatment regimens.\nPotential Side Effects and Safety Considerations\nWhile MIRTAZPRIME 30 offers numerous therapeutic benefits, patients should be aware of potential side effects that may occur during treatment. Understanding these effects helps patients make informed decisions and enables early identification of any concerning symptoms requiring medical attention.\nThe most commonly reported side effect is drowsiness or sedation, particularly during the initial weeks of treatment. This effect is typically most pronounced during the first few hours after taking the medication, which is why it's generally recommended for evening administration. Patients should exercise caution when driving, operating machinery, or engaging in activities requiring alertness until they understand how the medication affects them personally.\nIncreased appetite and weight gain represent another frequent side effect of MIRTAZPRIME 30. While beneficial for some patients, others may find this effect undesirable. Weight gain typically ranges from moderate to significant and appears to be dose-related. Patients concerned about weight should discuss dietary strategies and exercise plans with their healthcare provider.\nDry mouth is a common anticholinergic side effect that can cause discomfort but is generally manageable through increased fluid intake, sugar-free gum or candy, and good oral hygiene practices. Some patients may also experience dizziness, particularly when standing up quickly, due to the medication's effects on blood pressure regulation.\nConstipation may occur in some patients and can usually be managed through dietary modifications, increased fiber intake, adequate hydration, and regular physical activity. Less commonly, patients might experience confusion, abnormal dreams, or changes in thinking, particularly in older adults who may be more sensitive to the medication's effects.\nSerious side effects, while rare, require immediate medical attention. These include signs of allergic reactions such as rash, itching, swelling, severe dizziness, or difficulty breathing. Agranulocytosis, a dangerous decrease in white blood cells, is an extremely rare but serious complication that manifests as fever, sore throat, or signs of infection. Any unexplained fever or signs of infection should prompt immediate contact with a healthcare provider.\nSerotonin syndrome is another rare but potentially life-threatening condition that can occur when mirtazapine is combined with other medications affecting serotonin levels. Symptoms include agitation, hallucinations, rapid heartbeat, fever, excessive sweating, muscle stiffness, or coordination problems. Patients should inform their healthcare provider about all medications and supplements they are taking to avoid dangerous interactions.\nAbrupt discontinuation of MIRTAZPRIME 30 can lead to withdrawal symptoms, including nausea, anxiety, irritability, and flu-like symptoms. Therefore, any decision to stop the medication should be made in consultation with a healthcare provider who can develop an appropriate tapering schedule.\nImportant Usage Guidelines\nMIRTAZPRIME 30 should always be taken exactly as prescribed by a qualified healthcare professional. The medication is typically administered once daily, preferably in the evening before bedtime due to its sedative effects. Tablets should be swallowed whole with water and can be taken with or without food, though taking them with food may help reduce any stomach upset.\nConsistency in timing is important for maintaining stable blood levels of the medication and optimizing therapeutic effects. Patients should try to take their dose at approximately the same time each evening. If a dose is missed, it should be taken as soon as remembered unless it's close to the time for the next scheduled dose, in which case the missed dose should be skipped rather than doubling up.\nThe full therapeutic benefits of MIRTAZPRIME 30 may take several weeks to manifest. Patients should continue taking the medication as prescribed even if they don't feel immediate improvement. Premature discontinuation is a common reason for treatment failure in depression management.\nRegular follow-up appointments with the prescribing physician are essential for monitoring treatment response, adjusting dosages if necessary, and screening for potential side effects. Patients should maintain open communication with their healthcare team about their symptoms, concerns, and any changes in their condition.\nConclusion\nMIRTAZPRIME 30 represents a valuable therapeutic option in the comprehensive management of major depressive disorder and related conditions. Its unique mechanism of action, combining enhanced noradrenergic and serotonergic neurotransmission with sedative and appetite-stimulating properties, offers distinct advantages for carefully selected patients. The medication's ability to improve both mood symptoms and sleep disturbances makes it particularly useful for patients experiencing depression accompanied by insomnia.\nThe relatively favorable side effect profile, particularly regarding sexual function and gastrointestinal tolerability, enhances patient acceptance and adherence to treatment. While potential side effects such as sedation, increased appetite, and weight gain require monitoring and management, many patients find these effects tolerable compared to the debilitating symptoms of untreated depression.\nSuccess with MIRTAZPRIME 30, as with any antidepressant therapy, depends on proper patient selection, appropriate dosing, regular monitoring, and a comprehensive treatment approach that may include psychotherapy, lifestyle modifications, and social support alongside pharmacological intervention. Patients should work closely with their healthcare providers to optimize treatment outcomes and maintain long-term mental health wellness.\nThe decision to use MIRTAZPRIME 30 should always be made collaboratively between patient and physician, considering individual symptoms, treatment history, coexisting medical conditions, and personal preferences. With proper use under medical supervision, MIRTAZPRIME 30 can be an effective tool in helping patients reclaim their lives from the devastating effects of depression and move toward recovery and renewed well-being.", "price": 262.0, "discountamount": 79.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2254, "imageuri": "https://productimages.withfloats.com/actual/694d14f83d39ca31a28d046b.png", "tileimageuri": "https://productimages.withfloats.com/tile/694d14f83d39ca31a28d046b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-25T10:41:58.966Z", "updatedon": "2026-02-13T07:27:39.531Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/mirtazapine-30mg/2254", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "MIRTAZPRIME 30", "category": "NEUROLOGYRANGE", "tags": [ "MIRTAZPRIME 30", "Mirtazapine 30mg as per Indian Pharmacopoeia (IP) standards", "managing depression", "insomnia and anxiety.", "depression or anxiety.", "depredepressive episodes.", "helping patients reclaim their lives from the devastating effects of depression." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694cf85408591c1173b54c2f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Pregabalin Epalrestat and Methylcobalamin Tablets", "description": "EPSTATE ED represents an advanced pharmaceutical formulation that combines three powerful therapeutic agents: Pregabalin, Epalrestat, and Methylcobalamin. This innovative triple-combination medication is specifically designed to address the complex pathophysiology of diabetic neuropathy and neuropathic pain conditions. By integrating multiple mechanisms of action, EPSTATE ED offers a comprehensive approach to managing nerve-related complications that significantly impact the quality of life for millions of individuals worldwide.\nThe formulation addresses not only the symptomatic relief of neuropathic pain but also targets the underlying metabolic derangements that contribute to nerve damage progression. This multi-pronged therapeutic strategy makes EPSTATE ED particularly valuable for patients who require more than symptomatic management alone.\nUnderstanding the Active Components\nPregabalin: The Neuropathic Pain Modulator\nPregabalin serves as the cornerstone analgesic component in EPSTATE ED. This anticonvulsant medication works by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. Through this mechanism, Pregabalin reduces the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. This reduction in neurotransmitter release effectively dampens the abnormal neural signaling that characterizes neuropathic pain conditions.\nThe molecule demonstrates excellent bioavailability and rapid absorption, allowing patients to experience relief within a relatively short timeframe. Its efficacy in managing various neuropathic pain syndromes has been extensively documented in clinical trials, establishing it as a first-line agent for diabetic peripheral neuropathy, postherpetic neuralgia, and other chronic neuropathic pain conditions.\nEpalrestat: The Aldose Reductase Inhibitor\nEpalrestat represents a unique addition to the formulation, functioning as a selective aldose reductase inhibitor. In diabetic conditions, excess glucose is converted to sorbitol through the polyol pathway, with aldose reductase serving as the rate-limiting enzyme. The accumulation of sorbitol within nerve cells leads to osmotic stress, depletion of myoinositol, and subsequent nerve dysfunction.\nBy inhibiting aldose reductase, Epalrestat prevents this harmful sorbitol accumulation, thereby addressing one of the fundamental metabolic abnormalities responsible for diabetic neuropathy. This disease-modifying approach distinguishes EPSTATE ED from purely symptomatic treatments. Epalrestat has been particularly well-studied in Asian populations and has demonstrated the ability to improve nerve conduction velocities and reduce subjective neuropathic symptoms over time.\nMethylcobalamin: The Neurotropic Vitamin\nMethylcobalamin, the bioactive form of Vitamin B12, completes the therapeutic triad in EPSTATE ED. Unlike cyanocobalamin, which requires conversion in the body, methylcobalamin is immediately available for utilization in crucial biochemical processes. It plays an indispensable role in myelin synthesis, the protective sheath surrounding nerve fibers that enables proper signal transmission.\nThis coenzyme participates in methionine synthesis and is essential for maintaining the structural and functional integrity of neurons. Methylcobalamin also facilitates nerve regeneration and has demonstrated neuroprotective properties in various experimental models. For patients with diabetic neuropathy, who often exhibit Vitamin B12 deficiency (sometimes exacerbated by metformin therapy), supplementation with methylcobalamin addresses both nutritional deficits and supports nerve health at a fundamental level.\nClinical Applications and Uses\nEPSTATE ED is primarily indicated for the comprehensive management of diabetic peripheral neuropathy, a condition affecting approximately 50% of individuals with long-standing diabetes. The symptoms of this condition range from tingling sensations and burning pain to numbness and loss of protective sensation, which can lead to serious complications including foot ulcers and amputations.\nBeyond diabetic neuropathy, EPSTATE ED may be prescribed for various neuropathic pain syndromes where the combination of pain relief, metabolic correction, and nerve support proves beneficial. Patients experiencing chronic nerve pain resulting from metabolic disturbances, nutritional deficiencies, or structural nerve damage may find this combination particularly effective.\nThe medication is typically recommended for adults who have not achieved adequate symptom control with single-agent therapy or who would benefit from the synergistic effects of the three components. Healthcare providers may prescribe EPSTATE ED when a patient requires both immediate symptom relief and long-term disease modification.\nKey Benefits and Therapeutic Advantages\nComprehensive Multi-Mechanism Action\nThe primary advantage of EPSTATE ED lies in its multi-faceted approach to neuropathic conditions. Rather than addressing only pain symptoms, the formulation simultaneously tackles pain perception, underlying metabolic abnormalities, and nutritional support for nerve health. This comprehensive strategy may lead to superior outcomes compared to monotherapy approaches.\nEnhanced Pain Relief\nClinical evidence supporting Pregabalin's efficacy in neuropathic pain is substantial. Patients often report significant reductions in pain intensity, improved sleep quality due to decreased nocturnal pain, and enhanced ability to perform daily activities. The pain-relieving effects typically manifest within the first week of therapy and continue to improve with ongoing treatment.\nDisease Modification Potential\nUnlike purely symptomatic treatments, the inclusion of Epalrestat provides genuine disease-modifying potential. By targeting the polyol pathway, EPSTATE ED may slow the progression of nerve damage in diabetic patients. Long-term use may preserve nerve function and prevent the worsening of neuropathic symptoms, offering hope beyond mere symptom management.\nImproved Nerve Conduction and Function\nThe combination of metabolic correction through Epalrestat and neurotropic support via Methylcobalamin creates an environment conducive to nerve regeneration and functional improvement. Studies have demonstrated improvements in nerve conduction velocity parameters with similar combination therapies, suggesting potential restoration of nerve function rather than simple symptom masking.\nConvenience of Combination Therapy\nFor patients who would otherwise require multiple separate medications, EPSTATE ED offers the convenience of a single tablet containing all three therapeutic agents. This simplification of medication regimens improves compliance, reduces pill burden, and may enhance overall treatment outcomes.\nQuality of Life Enhancement\nThe cumulative effect of pain reduction, improved nerve function, and better metabolic control translates into meaningful quality of life improvements. Patients report better mobility, reduced interference of pain with daily activities, improved mood, and enhanced social functioning.\nPotential Side Effects and Safety Considerations\nCommon Side Effects\nAs with any pharmaceutical agent, EPSTATE ED may produce certain adverse effects. The most commonly reported side effects are primarily attributable to the Pregabalin component and include dizziness, somnolence, peripheral edema, dry mouth, blurred vision, weight gain, and difficulty with concentration or attention. These effects are generally mild to moderate and often diminish with continued therapy as the body adapts to the medication.\nGastrointestinal symptoms such as constipation or nausea may occur, though they are typically manageable with dietary modifications or symptomatic treatment. Some patients experience increased appetite leading to weight gain, which requires monitoring, particularly in diabetic individuals where weight management is crucial.\nSerious but Rare Adverse Events\nThough uncommon, certain serious adverse effects warrant immediate medical attention. These include allergic reactions manifesting as rash, itching, swelling, severe dizziness, or breathing difficulties. Pregabalin has been associated with rare cases of angioedema, which requires prompt discontinuation and medical intervention.\nMental health changes, including mood alterations, anxiety, depression, agitation, or suicidal thoughts, have been reported with Pregabalin use, particularly in individuals with pre-existing psychiatric conditions. Patients and caregivers should remain vigilant for behavioral changes and report them immediately to healthcare providers.\nDrug Interactions and Precautions\nEPSTATE ED may interact with other central nervous system depressants, including alcohol, opioids, benzodiazepines, and antihistamines, potentially intensifying sedation and cognitive impairment. Patients should inform their healthcare provider of all medications, supplements, and substances they consume.\nIndividuals with kidney impairment require dose adjustments since Pregabalin is primarily eliminated through renal excretion. Regular monitoring of renal function may be necessary during long-term therapy.\nSpecial Population Considerations\nPregnant or breastfeeding women should use EPSTATE ED only when clearly necessary and under strict medical supervision, as the safety profile in these populations has not been fully established. Elderly patients may be more susceptible to side effects, particularly dizziness and confusion, necessitating careful dose titration and monitoring.\nPatients should be advised against abrupt discontinuation of EPSTATE ED, as sudden cessation of Pregabalin may precipitate withdrawal symptoms including insomnia, nausea, headache, anxiety, and sweating. Gradual dose reduction under medical supervision is recommended when discontinuing therapy.\nDosage and Administration Guidelines\nThe appropriate dosage of EPSTATE ED is highly individualized and should be determined by a qualified healthcare professional based on the patient's specific condition, response to therapy, and tolerance. Typically, treatment begins with a lower dose that is gradually increased to achieve optimal therapeutic benefit while minimizing adverse effects.\nPatients should take EPSTATE ED exactly as prescribed, with or without food, at consistent times each day to maintain stable blood levels. Missing doses should be addressed by taking the forgotten dose as soon as remembered, unless it's nearly time for the next scheduled dose. Double dosing to compensate for missed doses is not recommended.\nRegular follow-up appointments allow healthcare providers to assess treatment efficacy, monitor for adverse effects, and make necessary dose adjustments. Patients should maintain open communication with their medical team regarding symptom improvement, side effects, and any concerns that arise during therapy.\nPatient Counseling and Lifestyle Recommendations\nMaximizing the benefits of EPSTATE ED extends beyond simply taking the medication. Patients should be counseled on complementary lifestyle measures that support neuropathy management. Maintaining optimal glycemic control remains paramount for diabetic patients, as blood sugar management directly impacts neuropathy progression regardless of medication.\nRegular physical activity, within individual capabilities, promotes circulation, supports nerve health, and may enhance the therapeutic effects of EPSTATE ED. Daily foot examinations become critical for diabetic patients to identify potential injuries early, preventing serious complications.\nNutritional optimization, including adequate intake of B vitamins, antioxidants, and essential nutrients, supports the neurotropic effects of Methylcobalamin. Avoiding alcohol and tobacco, both of which can exacerbate neuropathy, is strongly recommended.\nPatients should be cautioned about activities requiring alertness, such as driving or operating machinery, especially during the initial treatment phase when dizziness and somnolence may be more pronounced. These effects typically improve with continued therapy, but individual responses vary.\nConclusion\nEPSTATE ED represents a thoughtfully designed pharmaceutical formulation that addresses the multifaceted nature of diabetic neuropathy and neuropathic pain through its unique combination of Pregabalin, Epalrestat, and Methylcobalamin. This triple-action approach offers patients more than symptomatic relief—it provides genuine disease modification potential, nutritional support, and comprehensive nerve health optimization.\nThe synergistic effects of these three components create a therapeutic profile that is greater than the sum of its parts. While Pregabalin efficiently manages pain symptoms and improves quality of life in the short term, Epalrestat works to address underlying metabolic derangements that drive disease progression, and Methylcobalamin provides essential neurotropic support for nerve regeneration and function.\nFor patients struggling with the debilitating effects of neuropathic pain and diabetic neuropathy, EPSTATE ED offers renewed hope for better symptom control and potentially slowed disease progression. The convenience of combination therapy in a single tablet improves adherence and simplifies complex treatment regimens.\nHowever, EPSTATE ED is not without considerations. Potential side effects, though generally manageable, require awareness and monitoring. The medication is most effective when integrated into a comprehensive management plan that includes optimal glycemic control, lifestyle modifications, and regular medical supervision.\nUltimately, EPSTATE ED should be viewed as a valuable tool in the therapeutic arsenal against neuropathic conditions, best utilized under the guidance of knowledgeable healthcare professionals who can individualize treatment to each patient's unique needs and circumstances. With proper use, monitoring, and patient education, EPSTATE ED can significantly improve outcomes and quality of life for those affected by these challenging neurological conditions.", "price": 275.0, "discountamount": 82.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2253, "imageuri": "https://productimages.withfloats.com/actual/694cf859d25fa0b0657b1ac8.png", "tileimageuri": "https://productimages.withfloats.com/tile/694cf859d25fa0b0657b1ac8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-25T08:39:48.947Z", "updatedon": "2026-01-10T06:06:36.677Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/pregabalin-epalrestat-and-methylcobalamin-tablets/2253", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "EPSTATE ED", "category": "NEUROLOGYRANGE", "tags": [ "regabalin, Epalrestat, and Methylcobalamin.neuropathic pain conditions.", "Pregabalin, Epalrestat, and Methylcobalamin.", "neuropathic pain.", "diabetic neuropathy.", "sorbitol within nerve cells leads to osmotic stress.", "Epalrestat and neurotropic support via Methylcobalamin creates an environment .", "mood alterations, anxiety, depression, agitation.", "supports the neurotropic effects of Methylcobalamin." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }